In a recent pioneering study, Insilico has demonstrated the remarkable potential of generative biologics to rapidly design peptides targeting GLP1R—the receptor modulated by blockbuster diabetes drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback